The objective of the list is to help countries develop or update their national essential diagnostics lists, raise awareness and political will, guide procurement and regulation policies and improve access to the most important in vitro diagnostics that all countries need to make available to their populations, particularly in low-resourced countries. It will also contribute towards health systems strengthening and realizing universal health coverage.

Technical report of the fourth meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2022 (including the fourth WHO model list of essential in vitro diagnostics (EDL 4)). This report also includes the applications received for the EDL 4 and a summary of the deliberations and recommendations by the SAGE IVD members and the methodologist that assessed the supportive evidence for the EDL 4 applications.

In May 2018 the World Health Organization (WHO) published the first ever Model List of Essential In Vitro Diagnostics (EDL). The objective of the list is to help countries develop or update their national essential diagnostics lists raise awareness and political will guide procurement and regulation policies and improve access to the most important in vitro diagnostics that all countries need to make available to their populations particularly in low-resourced countries. It will also contribute towards health systems strengthening and realizing universal health coverage. The 1st EDL list includes 62 test categories divided into two levels and two categories: - Level I: primary care settings where no or minimal laboratory services are available - Level II: facilities with laboratories - Category a: general IVDs - Category b: disease-specific IVDs

Transfusion Medicine and Hemostasis, Fourth Edition continues to be the only "pocket-size" quick reference for pathology and transfusion medicine for residents and fellows. It's helpful to all physicians and allied health professionals who order and administer blood components, cellular therapies, and specialized factors for hemostatic abnormalities; who order coagulation testing; and those who consult and care for these often very ill patients. The book is ideal for pathology, medicine, surgery, and anesthesia residents; transfusion, hematology, and anesthesia fellows; and certified and specialized practitioners; as well as medical technologist in transfusion, cellular therapy, hematology, and coagulation. The new edition covers the many new developments that have occurred since the previous edition to include new blood products, new indications or clinical conditions in which blood products are used. Similarly, new hemostasis testing is introduced as well as new clinical scenarios due the COVID-19 pandemic relevant to Hemostasis & Transfusion Medicine. This includes COVID coagulopathy, Vaccine Induced Thrombotic Immune Thrombocytopenia, Pediatric reference range in coagulation testing, Platelet rich plasma and MNC products – CAR-T cells. - Includes COVID-19 coagulopathy and Vaccine Induced Thrombotic Immune N94 Thrombocytopenia - Provides all information regarding the clinical and laboratory aspects of Transfusion Medicine and Hemostasis in one place - Presents user-friendly, up-to-date information in a book that can be carried around either to the lab or bedside

This guidance document has been produced by the World Health Organization (WHO) to assist blood services in the development of national plans to respond to any disaster, major incident or emergency that threatens sufficiency or safety of the blood supply. Such situations can be caused by natural forces, by factors influenced by humans or directly caused by humans. This document is intended to guide the national blood service through the process of planning how to respond in a timely, controlled and appropriate way to emergencies. In the preparation of the document, WHO has tried to include the elements that blood services or providers might need to consider, providing some background on the reasons for their inclusion and guidance on different response options that may be available. The consequences of an emergency may include interruption of blood supply due to a shortage of blood donors, or to a disrupted supply of critical materials and equipment used in blood collection, component preparation and laboratory testing, resulting in reduced availability of blood and blood components. Although the demand for transfusion may decrease in some situations, transfusions continue to be necessary for clinical emergencies and for those patients reliant on long-term transfusion support. In contrast, some emergencies, for instance those resulting in multiple casualties, could lead to a rapid surge in demand for blood over a short time. The challenge is to maintain essential transfusion services as well as responding to the emergency. Preparedness, including business continuity planning, is essential for blood services to mitigate the impact of emergencies. Preparation should be underpinned by locally sensitive risk assessment using relevant data at the local or country level. However, it is not possible to predict the nature of every situation that could impact on the blood supply, and it is therefore expected that blood services will review the elements in this document as well as assessing their own situation, needs, capabilities and resources, along with any additional relevant country-specific factors, in the development of their own response plans. Planning should consider the concurrence and combinations of events and the response should be proportionate and coordinated with others. The aim is to maintain critical services and prepare for recovery. Staff training and support is key to resilience. It is acknowledged that as well as affecting the sufficiency and safety of blood supply, major incidents in countries undertaking transplantation may threaten the safety and sufficiency of the supply of other products of human origin, such as cells, tissues and organs. Increasingly, blood services are taking overall national responsibility for transplantation in their capacity as the organization responsible for the collection, processing, storage and supply of cells, tissues and organs. This approach is both sensible and appropriate, as the overall donor selection and screening processes are the same or very similar. This guidance document can therefore also be used to assist those bodies responsible for the provision of cells, tissues and organs to prepare for emergencies. Resilience to disasters and emergencies requires a commitment to the blood supply and transfusion system as an integral part of the health care system.